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Depressive symptoms are associated 
with poor glycemic control among women 
with type 2 diabetes mellitus
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Abstract 
Objective: In patients with type 2 diabetes mellitus, depressive symptoms may be associated with metabolic dete‑
rioration. The impact of sex on this association is unclear. The aim of this study is to analyze the relationship between 
depression and metabolic control by sex. The data presented is the side product of the clinical investigation by Rui 
Duarte, MD, Treatment Response in Type 2 Diabetes Patients with Major Depression from 2007.
Results: A sample of 628 outpatients with type 2 diabetes mellitus was taken from a specialized diabetes outpatient 
clinic. In a univariate analysis: women’s glycohemoglobin mean levels were 8.99% whereas men’s were 8.41% and 
the difference was statistically significant. The proportion of women (34.3%) with pathological levels of depression 
(Hospital Anxiety Depression Scale score ≥ 8) was significantly higher than men’s (15.2%). A linear regression analysis 
performed by sex and controlling for demographic, clinical and psychological variables, showed poorer metabolic 
control in women with depressive symptoms. No association was observed in men. These results support depression 
as a predictor for poor metabolic control in women and the need for detecting depressive symptoms when glycemic 
levels deteriorate.
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Introduction
Comorbidity between diabetes and depression is com-
mon [1] and sex differences in type 2 diabetes mellitus 
(T2DM) have been reported frequently [2].
A recent prevalence study of the Portuguese population 
demonstrated that the proportion of undiagnosed T2DM 
patients is 43.6% with a point prevalence of 11.7% with 
a significant difference between men (14.2%) and women 
(9.5%) [3]. Another recent epidemiological survey found 
a prevalence of depression disorders in Portugal around 
7.9%, women being at a higher risk of developing depres-
sion than men (OR  =  2.30) [4]. There are no studies 
reporting the prevalence of diabetes and depression 
comorbidity in the Portuguese population.
Although estrogens lower the risk of coronary heart 
disease, diabetes eliminates that protective effect on 
women [5]. Estrogen replacement therapy showed a pre-
ventive effect on T2DM incidence in postmenopausal 
women [6] and was also associated with a decrease in 
depressive symptoms in perimenopausal women [7].
Negative coping strategies such as resignation, pro-
test and isolation, were reported to be more prevalent in 
women with T2DM when compared to men [8]. Women 
also presented more difficulty on diet management and 
self-monitoring of blood glucose. They experienced their 
disease as an unforeseeable setback [9, 10] thus being less 
likely to reach glycemic goals with insulin treatment [11].
In women without diabetes, depressive symptoms are 
associated with a higher risk for metabolic syndrome. 
A greater waist circumference, higher fasting blood 
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glucose, higher diastolic blood pressure, lower HDL-
cholesterol and higher salivary cortisol were observed in 
women with depressive symptoms. No similar pattern 
was observed in men [12–14].
The few studies evaluating depressive symptoms 
by sex as associated with poorer glycemic control in 
T2DM showed conflicting results [15–18]. The finding 
of a sex difference would translate into better-adapted 
approaches, such as emphasizing the regular screening 
for depression in women with diabetes [19].
The present study aimed at detecting whether the pres-
ence of depressive symptoms was associated with poor 
glycemic control according to sex in a population with 




A screening protocol to detect depression and anxiety 
states in patients with T2DM was undertaken at the Por-
tuguese Diabetes Association (APDP) and included in a 
multicenter screening study whose results were published 
elsewhere [20]. This protocol aimed to provide and evalu-
ate specific clinical care for the comorbidity T2DM and 
depression. Inclusion criteria were age between 18 and 
65  years; at least 6  months of T2DM diagnosis (type 1 
diabetes (T1DM) was excluded); at least a 3 months’ fol-
low-up at APDP; regular hemoglobin A1c (HbA1c) test-
ing; and ability to understand and fill up questionnaires.
Portugal is a small southern European country with 
10 million inhabitants. APDP is a private social solidar-
ity institution, specialized in outpatient diabetes treating, 
founded in 1926 in Lisbon, and to where several general 
practitioners from southern Portugal sent patients regu-
larly. More than 15,000 persons with T2DM and 4,000 
with T1DM are yearly followed up at APDP. It also pro-
vides regular training on diabetes and patient education 
to nurses and medical doctors.
Methods
While waiting for their diabetes consultation, patients 
were approached and selected by trained clinical psy-
chologists taking into account the inclusion criteria. Eligi-
ble patients were consecutively invited to participate and 
those who accepted were given a brief explanation about 
the negative influence of the comorbidity between dia-
betes and depression on health outcomes. Socio-demo-
graphic and clinical data, namely body mass index (BMI), 
HbA1c level, diabetes type, therapy and antidepressant 
medication, were collected. Chronic complications (retin-
opathy, nephropathy, neuropathy and cardiovascular) due 
to diabetes were identified from the patient’s medical his-
tory, physical findings and automated laboratory data.
Patients filled up the Portuguese version of the Hospi-
tal Anxiety Depression Scale (HADS) [21, 22]. HADS is 
a self-report Likert scale (0–3) used in previous studies 
for detection of depression and anxiety symptoms, con-
sisting of 14 questions, 7 for anxiety and 7 for depression. 
Each sub-scale score ranges from 0 to 21, higher scores 
representing more severe symptoms. A score ≥ 8 on any 
of the sub-scales is considered pathological [22]. Only the 
depression symptoms sub-scale of HADS was used in the 
present study.
The HbA1c levels were determined at the APDP using 
an ion-exchange high-performance liquid chromatog-
raphy in a BIO-RAD Variant II turbo kit. According 
to the manufacturing data, normal range is 4.9–6.2% 
(30–44 mmol/mol).
Statistical analysis
Results are presented as the mean  ±  standard devia-
tion or as a percent as appropriate. Results between 
groups were compared using the Student’s t test or the 
Chi squared test. The Kolmogorov–Smirnov test was 
conducted to verify the normal distribution of the con-
tinuous variables. Prior to further analysis, non-normal 
distributed variables were log-transformed.
Linear regressions analyses were performed separately 
by sex with a model with all predictors entered concur-
rently. HbA1c was used as the dependent variable. Inde-
pendent variables were the demographic and clinical 
characteristics, as well as depression and anxiety symp-
toms. To avoid multicollinearity, the only antidiabetic 
treatment variables considered were the combination 
therapy with oral antidiabetic agents (OAA) and insulin 
[23].
Results were considered statistically relevant when the 
p-value was < 0.05 using a 95% confidence interval. SPSS 




From July 2007 to July 2009 a total of 656 patients meet-
ing the inclusion criteria were identified. From these, 
15 refused to participate (response rate =  97.7%). Their 
demographic features were not different from those 
included in the study. Due to missing data, 13 patients 
were further eliminated. Therefore, this study com-
prised a clinic-based convenience sample of 628 persons 
with T2DM, men representing 52.4%, aged 57.69 ± 5.55 
(range 36–65 years) (Table 1).
Patients treated with insulin represented 58.7% of the 
sample, and 36.6% were also taking an OAA. The mean 
HbA1c level was 8.69% (50  mmol/mol) (SD  =  1.66). 
Only 13.4% of the patients had an HbA1c level below 7% 
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(53  mmol/mol). Depressive symptoms above the score 
threshold were present in 24.4%.
Sex differences
Women had significantly higher HbA1c values 
[mean  =  8.99% (75  mmol/mol), SD  =  1.79] than men 
[mean  =  8.41% (69  mmol/mol), SD  =  1.48] with a 
p-value  =  0.0019. More men (16.7% men vs. 9.7% 
women, p = 0.010) reached significantly the therapeutic 
goal of HbA1c  <  7% (53  mmol/mol). Women had sig-
nificantly more depressive symptoms above the cut-off 
point (34.4% women vs. 15.2% men, p < 0.001). They are 
also three times more likely to take antidepressants than 
men (15.7% women vs. 5.2% men, significant p < 0.001). 
Men (31%) had more multiple (≥  2) chronic complica-
tions than women (20.1%, significant p = 0.002). Women 
(43.5% vs. 31% men, p =  0.001) used significantly more 
combined therapy (OAA and insulin).
Depressive symptoms and other predictors of metabolic 
control by sex
Glycemic control was positively associated with depres-
sive symptoms (standard beta  =  0.12, significant 
p = 0.031) and negatively associated with comorbidities 
(standard beta  =  −  0.13, significant p  =  0.020) in 
women. A positive significant association with higher 
HbA1c was found with combined treatment with OAA 
and insulin (standard beta =  0.16, p =  0.003) in men. 
A younger age was significantly associated with poorer 
glycemic control both in men (standard beta = − 0.24, 
p  =  <  0.001) and women (standard beta  =  −  0.19, 
p = 0.002) (Table 2).
Discussion
This cross-sectional study evaluated the association of 
depressive symptoms and glycemic control by sex, adjust-
ing for possible confounders, in a sample of patients with 
T2DM.
Globally participants had extremely poor glycemic 
control. The relatively low education level of the sam-
ple could account for this result. In a study by Mezuk 
et  al. [24], subjects with major depressive disorder and 
low educational attainment had a higher risk of T2DM. 
However, in our study, neither in men nor in women 
was detected any association between education level 
and glycemic control. As socioeconomic status usually 
encompasses educational attainment and can be asso-
ciated with suboptimal preventive care and unhealthy 
lifestyle, if we had evaluated other features like income 
maybe we would have found an association with poorer 
glycemic control [25].
In our sample, women had poorer glycemic control 
than men as reported in previous studies [9]. Nonethe-
less, other studies describe similar HbA1c values in 
T2DM patients between sexes [9, 12, 15].
In our study, a statistically significant association was 
found in women between depressive symptoms and poor 
glycemic control, adjusting for age and education level, 
diabetes duration, chronic complications, comorbidities, 
combined antidiabetic therapy and antidepressant use. 
No similar association was found for men.
Combined therapy was more often used in women, but 
was independently associated with poor glycemic control 
only in men. These findings could suggest that women 
were more responsive to combined treatment although 
their poor glycemic control.
Women were three times more likely to take antide-
pressants than men, but only half (15.7%) of the women 
diagnosed with depression were taking antidepressants. 
Some studies suggest that half of the T2DM patients are 
not accurately diagnosed for depressive symptoms [17, 
26]. In a study by Katon et al., only a third of the patients 
with depression had been adequately treated with an 
anti-depressant for at least 3 months [17].
Prevalence of undiagnosed depression in both sexes 
may arise at least partly from the effects of depression 
on how people perceive their health. Li et al. found that 
Table 1 Data displayed represent the mean val-
ues ± standard deviation
The respective percentage of the sample (global, men and women) is displayed 
between parentheses. Chi square and Student’s t-tests were used to compare 
each parameter between men and women. p-values are italic formatted when 
significance level is < 0.05. Chronic complications: retinopathy, nephropathy, 
neuropathy and cardiovascular
HADS The Hospital Anxiety and Depression Scale, BMI body mass index, OAA oral 
antidiabetic agent, HbA1c hemoglobin A1c
Total Men Women p-value
N = 628 N = 329 N = 299
Age (yrs) 57.69 ± 5.55 57.86 ± 5.34 57.50 ± 5.77 0.385
Education level 
(yrs)
6.57 ± 3.87 6.84 ± 3.93 6.27 ± 3.78 0.035
BMI (kg/m2) 29.99 ± 4.90 29.34 ± 4.55 30.70 ± 5.18 0.001
Years from diag‑
nosis
13.89 ± 7.59 13.56 ± 7.59 14.26 ± 7.59 0.089
≥ 2 chr complica‑
tions
162 (25.8) 102 (31.0) 60 (20.1) 0.002
≥ 1 comorbidities 84 (13.4) 37 (11.2) 47 (15.7) 0.102
OAA alone 259 (40.9) 157 (47.7) 100 (33.4) < 0.001
Insulin alone 139 (22.1) 70 (21.3) 69 (23.1) 0.632
OAA and insulin 230 (36.6) 102 (31) 130 (43.5) 0.001
Antidepressant 64 (10.2) 17 (5.2) 47 (15.7) < 0.001
HbA1c 8.69 ± 1.66 8.41 ± 1.48 8.99 ± 1.79 < 0.001
HbA1c < 7 84 (13.4) 55 (16.7) 29 (9.7) 0.010
HADS depression 5.16 ± 3.93 4.18 ± 3.29 6.25 ± 4.27 < 0.001
HADS depres‑
sion ≥ 8
153 (24.4) 50 (15.2) 103 (34.4) < 0.001
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patients who reported poor or fair health had 2.8-fold 
greater likelihood of having undiagnosed depression [26].
Moreover, undiagnosed depression may be indirectly 
attributable to inability to correctly identify cases of 
depression as a function of sex. In a study based on a 
large British survey, men were more likely than women 
to misidentify depression in other men [27]. Beliefs such 
as hegemonic masculinity may affect men ability to self-
report depression, leading them to report less symptoms 
overall than women. Nevertheless, one study found that 
men with higher adherence to masculine norms report 
more symptoms on measures of depression [28]. Another 
study showed that more than 20% of men who described 
themselves as depressed would not receive a diagnosis of 
depression by current criteria standards [29] suggesting 
the need for discussing traditional depression symptoms 
in what concern men.
In our study, similar to others results [15, 17, 18], men 
were less than half as likely to be depressed as women 
(34.4% women vs. 15.2% men, p  <  0.001). The lower 
prevalence of depression in men may be attributable 
to underdiagnosis but we do not have any measure to 
declare or refute it.
Conclusion
Our study suggests that it may be clinically relevant to 
conduct a systematic screening for depressive symp-
toms in T2DM patients. Women who are under an opti-
mized antidiabetic therapy and still have HbA1c values 
above the control cut-off point need to be systematically 
checked for depression. Treating depressive symptoms, 
especially in middle-aged women, enables better hyper-
glycemic control and avoids metabolic deterioration.
Limitations
This study has some limitations. Firstly, potential bio-
logical or psychological processes, link depression and 
T2DM. Hypothalamic–pituitary–adrenal axis, the 
innate immune response and the autonomic nervous 
system, and the burden with diabetes and unhealthy 
lifestyle behaviors, such as diet, physical activity and 
smoking [30], were not evaluated in our study. Secondly, 
the cross-sectional nature of the study does not allow 
for causality inferences. Chronic hyperglycemia can 
also affect depressive symptoms rather than vice versa, 
namely by the increase of diabetes burden [31]. Only 
with a longitudinal design would it be possible to deter-
mine the associative direction between hyperglycemia 
and depressive symptoms. Thirdly, depressive symptoms 
were analyzed with a Likert scale, but a psychiatric inter-
view remains the gold standard for depression diagnosis 
in clinical practice.
Lastly, this represents a convenience sample from a 
single diabetes clinic with a population with poor glyce-
mic control and low education level. Our findings may 
or may not be generalizable to other settings or patient 
populations.
Nevertheless, the large sample size is one of the study’s 
strengths. As far as we know, this is the first report to 
analyze the relationship between depressive symptoms 
and glycemic control in a Portuguese population with 
T2DM.
Table 2 Multiple linear regressions analyses: associations of glycemic control and demographic, clinical and psychomet-
ric variables
Beta-S: Beta standard regression coefficients. Statistically significant results with p-values < 0.05 are highlighted in italics. Chronic complications: retinopathy, 
nephropathy, neuropathy and cardiovascular
HADS The Hospital Anxiety and Depression Scale, BMI body mass index, OAA oral antidiabetic agent
Men Women
Beta-S t p-value Beta-S t p-value
Age (yrs) − 0.24 − 4.28 0.001 − 0.19 − 3.20 0.002
Education level (yrs) − 0.03 − 0.62 0.534 − 0.08 − 1.38 0.170
BMI (kg/m2) − 0.07 − 1.32 0.187 − 0.01 0.13 0.896
Years from diagnosis 0.07 1.11 0.268 0.04 0.60 0.550
≥ 2 chr complications 0.11 1.97 0.050 0.02 0.40 0.687
≥ 1 comorbidities 0.10 1.90 0.059 − 0.13 − 2.33 0.020
OAA and insulin 0.16 3.14 0.003 0.10 1.75 0.081
Antidepressant 0.02 0.86 0.776 − 0.07 − 1.17 0.241
HADS depression − 0.01 − 0.11 0.985 0.12 1.77 0.031
Adjusted  R2 0.079 0.065
F‑change 4.119 3.289
p‑value (F‑change) < 0.001 0.001
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